Systemic Mastocytosis – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 37
Inquire Before Buying

Systemic Mastocytosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Mastocytosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis. Systemic Mastocytosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Mastocytosis.
- A review of the Systemic Mastocytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Mastocytosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Systemic Mastocytosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Systemic Mastocytosis 7
Systemic Mastocytosis Therapeutics under Development by Companies 9
Systemic Mastocytosis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Systemic Mastocytosis Therapeutics - Products under Development by Companies 14
Systemic Mastocytosis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Systemic Mastocytosis Therapeutics Development 16
Novartis AG 16
Pharmacyclics, Inc. 17
AB Science 18
Systemic Mastocytosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
midostaurin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-45261 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
masitinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PKC-412 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
thalidomide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Pharmacyclics, Inc., H2 2012 17
AB Science, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35

List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Global Budget Hotel Market Driven by Increase in Business Travel
    In the aftermath of the global economic crisis, the hotel industry had witnessed declining growth, particularly in the luxury hotel segment. However, in the past couple of year, the hotel market has recovered, bolstered by a rise in demand. With rise in disposable income in Asian countries, increase in business travel and growing demand for [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • China Pharmaceutical Excipients Industry Report, 2014-2017
    Published: 19-Nov-2014        Price: US $2300 Onwards        Pages: 101
    Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment. China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-......
  • China Recombinant Protein Drug Industry Report, 2014-2017
    Published: 19-Nov-2014        Price: US $2500 Onwards        Pages: 127
    The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014. The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for exam......
  • High Throughput Mass Spec-Based Screening Assay Trends 2014
    Published: 19-Nov-2014        Price: US $2500 Onwards        Pages: 53
    Executive Summary This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on high throughput (HT) mass spectrometry (MS)-based screening assays carried out in November 2014. The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces and to update our previous report in MS-based screening assays (published February 2013). The questionnaire was compiled to meet the needs, requirements and interests of ......
  • Cote d’Ivoire Pharmaceuticals and Healthcare Report Q1 2015
    Published: 19-Nov-2014        Price: US $1295 Onwards        Pages: 59
    BMI View: Côte d'Ivoire's healthcare sector will continue to be underfunded, making it difficult for the country to achieve its healthcare-related millennium development goals. This poses questions regarding the population's access to treatment of infectious and chronic diseases. While the planned implementation of universal healthcare coverage in 2015 will increase access to healthcare services, therefore providing drugmakers with increased revenue-earning opportunities, we believe a continued......
  • Global Oncology Biosimilars Market 2014-2018
    Published: 19-Nov-2014        Price: US $2500 Onwards        Pages: 71
    Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in o......
  • Hungary Pharmaceuticals and Healthcare Report Q1 2015
    Published: 19-Nov-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: We expect the decline in Hungary's pharmaceutical market to stabilise in 2015, although a challenging operating environment and regulatory burden will weigh on market growth. Our country risk team also sees potential headwinds to spending growth, namely Hungary's excessive government deficits and a German economic slowdown that will reverberate throughout the Central and Eastern European region. Pricing pressures and slow uptake of new medicines will continue to present near-term headw......
  • Global Irritable Bowel Syndrome Market 2015-2019
    Published: 19-Nov-2014        Price: US $2500 Onwards        Pages: 83
    Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloa......
  • Italy Pharmaceuticals and Healthcare Report Q1 2015
    Published: 19-Nov-2014        Price: US $1295 Onwards        Pages: 102
    BMI View: SN pharmaceutical expenditure will decline in 2014 - creating revenue pressures for drugmakers and pharmacies in Italy and increasing out-of-pocket costs for the population. The government aimed to slash public healthcare costs by EUR900mn (USD1.2bn) in 2012 and EUR1.8bn (USD2.4bn) in 2013 and aims to continue to contain healthcare spending by EUR2.0bn (USD2.7bn) in 2014 and EUR2.1bn (USD2.8bn) in 2015. Headline Expenditure Projections ? Pharmaceuticals: EUR20.91bn (USD27.60bn) in 2013......
  • Global Elderly and Disabled Assistive Market 2015-2019
    Published: 19-Nov-2014        Price: US $2500 Onwards        Pages: 65
    Elderly and disabled assistive devices enable the elderly and disabled population to carry out their everyday activities that involve movement, hearing, and reading with ease. The devices are designed for the elderly and disabled population to live more independently with a good quality of life. The devices include both simple and complex products in design. For instance, wheelchairs, crutches, and mobility scooters are among the simplest in design, while reading machines, hearing aids, and tran......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs